Literature DB >> 11893772

Properties of triglyceride-rich and cholesterol-rich lipoproteins in the remnant-like particle fraction of human blood plasma.

Elisa Campos1, Leila Kotite, Patricia Blanche, Yasushi Mitsugi, Philip H Frost, Umesh Masharani, Ronald M Krauss, Richard J Havel.   

Abstract

An immunoassay procedure that quantifies remnant-like particle (RLP) cholesterol in human blood plasma has shown considerable promise as a clinically applicable risk marker for atherosclerotic disease. The lipoproteins included in this assay include not only certain TG-rich lipoproteins [all particles containing apolipoprotein B-48 (apoB-48) and a fraction of those containing apoB-100] but also a very small proportion of plasma cholesterol-rich lipoproteins. The TG-rich lipoprotein component of RLP has been partially characterized, but relatively little is known about the component cholesterol-rich lipoproteins. We have further characterized the properties of the TG-rich component that is included in RLP in which about 25% of the particles contain apoB-48 and the remainder apoB-100. We show that the cholesterol-rich component is comprised mainly of beta-migrating LDLs that contain predominantly apoB-100. ApoE found in the LDL fraction of RLP resides on pre-beta lipoproteins that lack apoA-I as well as apoB. The TG-rich component of RLP is responsible for increased RLP-cholesterol concentrations associated with hypertriglyceridemia. By contrast, the cholesterol-rich component is a major contributor to plasma RLP-cholesterol in individuals with low plasma TG. Our results suggest that particle heterogeneity in the RLP fraction is likely to affect the ability of RLP-cholesterol concentration to predict atherosclerotic risk. RLP-cholesterol concentrations in individuals with low plasma TG may not have the same clinical significance as they do in those with hypertriglyceridemia.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11893772

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  6 in total

1.  Lipoproteins: When size really matters.

Authors:  J Bruce German; Jennifer T Smilowitz; Angela M Zivkovic
Journal:  Curr Opin Colloid Interface Sci       Date:  2006-06       Impact factor: 6.448

2.  Fasting and postprandial apolipoprotein B-48 levels in healthy, obese, and hyperlipidemic subjects.

Authors:  Seiko Otokozawa; Masumi Ai; Margaret R Diffenderfer; Bela F Asztalos; Akira Tanaka; Stefania Lamon-Fava; Ernst J Schaefer
Journal:  Metabolism       Date:  2009-07-09       Impact factor: 8.694

3.  8302A/C and (TTA)n polymorphisms in the HMG-CoA reductase gene may be associated with some plasma lipid metabolic phenotypes in patients with coronary heart disease.

Authors:  Yu Tong; Sizhong Zhang; Hai Li; Zhiguang Su; Xiangdong Kong; Hekun Liu; Cuiying Xiao; Yan Sun; Jia Jun Shi
Journal:  Lipids       Date:  2004-03       Impact factor: 1.880

4.  Effects of intensive atorvastatin and rosuvastatin treatment on apolipoprotein B-48 and remnant lipoprotein cholesterol levels.

Authors:  Seiko Otokozawa; Masumi Ai; Thomas Van Himbergen; Bela F Asztalos; Akira Tanaka; Evan A Stein; Peter H Jones; Ernst J Schaefer
Journal:  Atherosclerosis       Date:  2008-11-12       Impact factor: 5.162

5.  A Dipeptidyl Peptidase-4 Inhibitor, Teneligliptin, Decreases Plasma Triglyceride-Rich Lipoprotein Remnants in Diabetic Patients with Chronic Kidney Disease Undergoing Hemodialysis.

Authors:  Koichiro Homma; Joe Yoshizawa; Yutaka Shiina; Hideki Ozawa; Muneki Igarashi; Tadashi Matsuoka; Junichi Sasaki; Mamoru Yoshizawa; Yasuhiko Homma
Journal:  Drugs R D       Date:  2017-09

Review 6.  Pathophysiology of Diabetic Dyslipidemia.

Authors:  Tsutomu Hirano
Journal:  J Atheroscler Thromb       Date:  2018-07-12       Impact factor: 4.928

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.